Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Equity Ratio (2017 - 2026)

Denali Therapeutics has reported Equity Ratio over the past 9 years, most recently at 0.89 for Q4 2025.

  • Quarterly Equity Ratio fell 1.05% to 0.89 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.89 through Dec 2025, down 1.05% year-over-year, with the annual reading at 0.89 for FY2025, 1.05% down from the prior year.
  • Equity Ratio was 0.89 for Q4 2025 at Denali Therapeutics, up from 0.88 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.92 in Q2 2024 and troughed at 0.66 in Q3 2022.
  • The 5-year median for Equity Ratio is 0.88 (2025), against an average of 0.81.
  • Year-over-year, Equity Ratio fell 15.33% in 2021 and then surged 36.82% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.69 in 2021, then increased by 4.17% to 0.71 in 2022, then grew by 25.15% to 0.89 in 2023, then grew by 0.16% to 0.89 in 2024, then decreased by 1.05% to 0.89 in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Equity Ratio are 0.89 (Q4 2025), 0.88 (Q3 2025), and 0.88 (Q2 2025).